Percutaneous ultrasound-guided radiofrequency ablation for patients with liver metastases from gastrointestinal stromal tumors

Liu, Li; Wang, Bing; Zhang, Zhong-Yi; Wang, Song; Wu, Hao; Wang, Hong; Wu, Wei; Yan, Kun; Yang, Wei

doi:10.1080/02656736.2023.2292950

Cited by 1 publication

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, TACE has been found to be effective for patients with liver metastases who have experienced treatment failure with TKIs, with a potentially better prognosis for patients with liver-limited metastases ( 34 , 35 ). Although the long-term effect on OS has not been conclusively established, RFA treatment for liver metastases can achieve symptomatic relief with good tolerability ( 36 - 38 ). The application of radiotherapy in advanced GIST remains controversial.…”

Section: Discussionmentioning

confidence: 99%

Survival outcomes and prognostic factors of advanced gastrointestinal stromal tumors: in the era of multiple tyrosine kinase inhibitors

Li,

Huang,

Zhou

et al. 2024

J Gastrointest Oncol

View full text Add to dashboard Cite

Background Tyrosine kinase inhibitors (TKIs) have shown great efficacy in the treatment of advanced gastrointestinal stromal tumors (GISTs), significantly prolonging the survival of patients. In the era of imatinib, a few studies reported some prognostic factors for patients with advanced GISTs, such as age, sex, performance status, diameter of the largest lesions, KIT exon mutations, and some hematological examination results. However, with the advent of more TKIs, the prognostic factors for patients with advanced GISTs have not been fully understood in the era of multiple TKIs. In this study, we aimed to identify independent prognostic factors associated with the survival of patients diagnosed with advanced GISTs. Methods Data on clinicopathologic characteristics, treatment approaches, and survival were retrospectively collected for patients with primary unresectable or recurrent GISTs treated from January 2010 to July 2023 at the First Affiliated Hospital of Chongqing Medical University, China. Univariable and multivariable Cox proportional hazards regression models were used to identify independent prognostic factors of survival. Results A total of 194 patients were included in the analysis. The median follow-up duration was 59.9 months (range, 2.7–141.7 months). The median overall survival (mOS) in this cohort was 76.5 months (95% confidence interval, 63.4 to 89.6 months). All patients received TKI therapy during the follow-up period, and 56.2% received two or more types of TKIs. In multivariable Cox analysis, younger age, a single lesion at enrollment, no previous use of TKIs, smaller tumor burden, good Eastern Cooperative Oncology Group performance status (ECOG PS ≤1), and lesions limited to the liver were independent prognostic factors for better survival. Conclusions We found that a single lesion at enrollment, no previous use of TKIs, a smaller tumor burden, and lesions limited to the liver were associated with better survival. Drug resistance is a severe challenge for advanced GISTs, and several factors mentioned above may be correlated with the development of drug resistance, leading to the poor survival of patients.

show abstract